


Robust Radiomics Methods



Hugo Aerts

Director, Computational Imaging and Bioinformatics Lab (CIBL)
Dana-Farber Cancer Institute, Brigham and Women's Hospital
Harvard Medical School

Objectives

- Describe the motivation for integrating imaging with genomic and clinical data
- Describe robust methodology underlying quantitative radiomic analysis
- Describe biomarker quantification studies in Radiomics and Imaging-Genomics (Radiogenomics)

Imaging for personalized medicine


Advantages of Imaging:

- Performed non-invasively
- Covers the total 3D volume
- Already performed in clinical practice
- Multiple times during treatment for diagnosis, staging, radiation oncology planning, response assessment

Disadvantages of Imaging:

- Probes the cancer at the macroscopic level
- Often qualitative not quantitative
- Very heterogeneous acquisition protocols:
 - comparisons between patients difficult
 - comparisons same patient in time difficult
- Storage of only reconstructed images (not the raw data)


Representative CT images of lung cancer




Tumors are different

Medical imaging can capture these phenotypic differences

Integrating Imaging and Genomic Data



Imaging-Genomics




Integrating Tissue Imaging data with the underlying Biology

Radiomics rational

- Radiographic images are typically analysed qualitatively by radiologist, often with non-standard lexicon.
- At most, unidirectional measurements (RECIST)
- Radiomics aims to provide a comprehensive quantification of the tumor phenotype using automated image characterisation algorithms
- We hypothesize that radiomic analyses of standard of care images can improve diagnostic, prognostic and predictive power
- Automation is key: automatic quantitative feature algorithms to extract quantitative data instead of qualitative data, reduce observer variation by manual annotation, and increase speed of workflow.


Radiomics: Quantify the tumor phenotype

Convert Images to mineable data in high throughput (radiomics)




*Lambin et al. Eur J Cancer 2012
*Kumar et al. Magn Reson Imaging 2012

Radiomics: Workflow & Challenges



Radiomics: Workflow & Challenges




Automatic segmentation:

- 1) Automated method for high throughput of images.
- 2) Reducing the **high intra- and inter-observer variability** observed for target definition.




Automatic tumor delineation using 3D-Slicer



Developing algorithms for fast, semi-automated, and accurate delineation





Automatic tumor delineation using 3D-Slicer






3D-Slicer region growing algorithm






Radiomics: Workflow & Challenges



Radiomic Feature Set (current release ~1600 features)



Radiomic features can capture tumor phenotypic details



Robust Radiomics Data Analysis
(Feature Selection & Machine learning)


Motivation

- Predictive/Prognostic models having high accuracy, reliability and efficiency can be vital factors driving success of "Radiomics".
- Need for the machine-learning models.
- Radiomics suffers from the curse of dimensionality.
- Need for the feature selection.
- Different feature selection and machine-learning classification methods have to be investigated.




Radiomics Dimensionality Reduction

Matrix of 440 Radiomics features
(422 NSCLC patients)




Feature selection: RIDER test retest

- Rider test retest reproducibility to select the most reproducible tumor image features extracted from CT images of 31 non-small cell lung cancer (NSCLC) patients.
- CT scans acquired within fifteen minutes.
- All primary lung cancers were segmented using Definiens
- 440 radiomics features were extracted from these segmented tumor regions
- Intraclass Correlation Coefficient (ICC) was calculated for each feature as a stability index




Robust Machine Learning in Radiomics




*Parmar et al. submitted


Machine Learning in Radiomics





Stability for feature selection and Classification




Machine Learning in Radiomics




Imaging-Genomics across cancer types



Radiomics CT Workflow



Radiomics CT Signature Performance



Performance Model:
- CI = 0.65 on the Lung2 Validation Dataset (n=225)

*Aerts et al. Nature Comm. 2014

Radiomics CT Signature Performance


Extended Data Table 1 Prognostic performance in validation datasets (Concordance Index CI)									
Dataset	TNM	Volume	Radiomics	TNM- Radiomics		Volume- Radiomics		TNM vs. Radiomics	
				Radiomics	Radiomics	Radiomics	Radiomics	Radiomics	Radiomics
Lung2	0.60	0.63	0.65	0.64	0.65	1.42x10 ⁻⁰⁴	6.29x10 ⁻⁰⁵	1.40x10 ⁻⁰⁵	7.52x10 ⁻⁰⁶
H&N1	0.69	0.68	0.69	0.70	0.69	0.12	1.70x10 ⁻⁰¹	3.79x10 ⁻⁰⁴	8.55x10 ⁻⁰³
H&N2	0.66	0.65	0.69	0.69	0.68	6.48x10 ⁻⁰³	3.72x10 ⁻⁰³	3.06x10 ⁻⁰³	2.52x10 ⁻⁰³

Prognostic performance in validation datasets (Concordance Index CI)

- Signature performed significantly better compared to volume in all datasets.
- Signature performance was better than TNM staging in Lung2 and H&N2, and comparable in the H&N1 dataset.
- Combining the signature with TNM showed significant improvement in all datasets.

Additional Validation of Prognostic Signature

542 Oropharyngeal squamous cell carcinoma (OPSCC) treated at Princess Margaret Hospital (PMH) in Toronto.




C-index was: PMH1: 0.628 (P<2.72e-9), PMH2: 0.634 (P<2.7e-6) and PMH3: 0.647 (P<5.35e-6)


Radiomics signature could be validated in an additional large OPSCC cohort

*Leijnear et al. Acta Onco 2015


GSEA of Prognostic Radiomics Signature




Radiomics-Genomics in NSCLC



Association Heatmap Radiomics-Genomics



Strong correlation between Radiomic data and Molecular Pathways



Radiomics-Genomics association modules

13 association modules were identified and independently validated


Radiomics Modules associate with distinct biological processes

Modules are significantly associated with clinical parameters: survival (3), histology (5), stage (10)

Clinical-Radiomics-Genomics Prognostic Signatures


Genomic Signature:
Hou et al., 2010
17 genes for Post-treatment survival

Radiomics Signature:
Aerts et al., 2014
(I) Statistics Energy
(II) Shape Compactness
(III) Grey Level Nonuniformity
(IV) Wavelet Grey Level Nonuniformity HLH




Radiomics significantly adds to prognostic gene-signatures

Imaging-Genomics in GBM




Methods: Manual delineations




*Grossmann et al. Submitted

Prognostic value of volumetric features




*Grossmann et al. Submitted

Imaging-Genomics Pathway Analysis of MRI Derived Volumetric Tumor Phenotype Features in Glioblastoma




Volumetric features predict mutational status in GBM patients



N=76 GBM patients
from TCGA-GBM
cohort

*Gutman et al. Submitted

TP53 positive/negative



TP53 mutated tumors had significantly smaller CE and necrotic volumes ($p=0.012$ and 0.017 , respectively) compared to wild-type.

*Gutman et al. Submitted

Quantitative Imaging: Current Status & Outlook

- Imaging moves towards a computational data science (bioinformatics)
- Due to advances in imaging, quantitative imaging is currently possible
- Large retrospective and prospective potential
- Large number of imaging features defined & successfully implemented
- Robust feature extraction pipeline implemented in 3D-Slicer (Python / Matlab)
- Radiomics signatures are prognostic across cancer types
- Radiomics data is strongly association with driving biological processes
- Ongoing: "Delta radiomics" change of image features
- Ongoing: Preclinical models with tumor models having inducible KO
- Ongoing: Radiomics in clinical trial data

Take home message

The field of Forensic Bioinformatics (Keith Baggerly, MD Anderson)
Investigating the reproducibility and methodology of scientific studies in retrospect. They request the data from the investigators, they assess the used statistics, methods, results, and conclusions.
They find a large number of studies that are wrong or even fraud


Duke Scandal (Anil Potti)
Accused of falsifying data regarding the use of microarray genetic analysis for personalized cancer treatment. Publications in various prestigious scientific journals were retracted (including PNAS, Lancet Oncology, Nature Medicine, JAMA, JCO, NEJM).

Forensic Radiology



RESEARCH ARTICLE
False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review
Anastasia Chalkidou*, Michael J. O'Doherty, Paul K. Marsden
Division of Imaging Sciences and Biomedical Engineering, Kings College London 4th Floor, Lambeth Wing, St. Thomas Hospital, SE1 7EH, London, United Kingdom

Forensic Radiology





Computational Imaging &
Bioinformatics Laboratory
www.cibi-harvard.org

- Emmanuel Rios-Velazques, PhD
- Stephen Yip, PhD
- Elizabeth Huynh, PhD
- Patrick Grossmann, MSc
- Thibaud Coroller, MSc
- Chintan Parmar, MSc
- Ying Hou, MD
- Matthew Wagar, MSc
- Vivek Narayan, BSc



- Brian Alexander
- Tina Kapur
- Raymond Mak
- Fiona Fennessy
- Mike Makrigiorgos
- Ross Berbeco
- John Quackenbush
- Gisele Cruz
- Nabgha Farhat
- Ron Kikinis
- Aedin Culhane



- Philippe Lambin
- Ralph Leijenaar
- Sara Cavalho



- Robbert Gillies
- Yuhua Gu
- Virendra Kumar
- Olya Grove



- Princess Margaret Hospital
University Health Network
- Benjamin Haibe-Kains
 - Nehme Hachem
